Showing results (191-200 of 283) with videos related to

Sort By:
Pageof 29
International Journal of Cancer|November 14, 1997
G1 control gene status is frequently altered in resectable non-small cell lung cancerD C Betticher, G R White, S Vonlanthen, et al.
British Journal of Cancer|September 14, 2006
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancerS C White, P Lorigan, G P Margison, et al.
British Journal of Cancer|June 1, 1988
A phase I and pharmacokinetic study of amphethinileD B Smith, C Ewen, J Mackintosh, et al.
British Journal of Cancer|November 1, 1989
Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II studyN Thatcher, H Dazzi, R J Johnson, et al.
Cancer|September 15, 1985
Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancerN Thatcher, R D James, W P Steward, et al.
British Journal of Cancer|July 31, 2008
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancerS Baka, R Califano, R Ferraldeschi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2015
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancerJ Bendell, E M O'Reilly, M R Middleton, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patientsH Sharma, N Thatcher, J Baer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1993
Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC)M E Van Hoef, J A Radford, A Jones, et al.
Lung Cancer (Amsterdam, Netherlands)|June 22, 2006
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancerS Baka, C Manegold, E Buchholz, et al.
Pageof 29